Q-omics provides the consensus-scored OR11G2 profile across patient tissues and cancer cell-line models. OR11G2 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, OR11G2 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, OR11G2 RNA expression shows 6,272 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, KIRC, and STAD as cancer lineages where OR11G2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR11G2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR11G2 survival associations across molecular data types. OR11G2 RNA expression shows survival associations in the most cancer types (9), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR11G2 RNA expression–survival associations across cancer types. High OR11G2 expression shows unfavorable associations in KICH, SCLC, THCA, BRCA and SARC, but favorable associations in UCEC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for OR11G2 RNA expression.
This table summarizes OR11G2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OR11G2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR11G2 shows lower tumor expression in KIRC. The KIRC box plot shows higher OR11G2 RNA expression in normal versus tumor tissue (log2 FC = −0.009, t-test p = .011).
This table shows molecular features associated with OR11G2 in patient tissues and cancer cell lines. In patient samples, OR11G2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR11G2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
